Suppr超能文献

一项比较改良高剂量奥美拉唑与阿莫西林三联疗法和标准三联疗法根除幽门螺杆菌的随机对照试验结果

Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication.

作者信息

Chunlertlith Kitti, Limpapanasit Uaepong, Mairiang Pisaln, Vannaprasaht Suda, Tassaneeyakul Wichittra, Sangchan Apichat, Sawadpanich Kookwan, Suttichaimongkol Tanita, Pongpit Jamrus, Pattarapongsin Moragot

机构信息

Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, KhonKaen University, Thailand. Email:

出版信息

Asian Pac J Cancer Prev. 2017 Apr 1;18(4):927-932. doi: 10.22034/APJCP.2017.18.4.927.

Abstract

Background: Helicobacter pylori (H. pylori) infection is related to peptic ulcer diseases and gastric cancer and eradication of H. pylori should be expected to decrease the risk of their development. Factors affecting H. pylori eradication are antibiotic resistance, CYP2C19 genotypes, drug regimen and patient compliance. Increment of omeprazole and amoxicillin dosage in clarithromycin-containing triple therapy regimen may overcome these problems and may be a better choice than the conventional clarithromycin-containing triple therapy regimen. Objective: To compare the eradication rates with modified triple therapy (MTT) and standard triple therapy (STT) as first-line treatment. Materials and Methods: The study was an open label, multicenter, randomized controlled trial. A total of 170 patients infected with H. pylori diagnosed by rapid urease test were randomly assigned into 2 groups. The first was treated with a 14-day MTT (20 mg omeprazole t.i.d., 500 mg amoxicillin t.i.d., and 500 mg clarithromycin b.i.d.) and the second with a 14-day STT (20 mg omeprazole b.i.d., 1000 mg amoxicillin b.i.d., and 500 mg clarithromycin b.i.d.). H. pylori eradication was evaluated by 14C-urea breath test. CYP2C19 genotypes, clarithromycin resistance, side effects and patient compliance were also recorded. Results: There were 85 patients in each group. The H. pylori eradication rate in the MTT group was 84.7% by ITT analysis and 91.1% by PP analysis, compared to the STT group values of 76.5% and 87.8% (p = 0.18 and 0.51), respectively. CYP2C19 genotypes and patient compliance were similar in both groups. Prevalence of clarithromycin resistance was 7.0%. Side effects were all mild with no significant differences between the twogroups. Conclusions: MTT is not superior to STT. From this study, MTT may not be recommended as the first-line treatment for H. pylori infection in Thailand because eradication rates proved to be less than 90% by ITT analysis.

摘要

背景

幽门螺杆菌(H. pylori)感染与消化性溃疡疾病及胃癌相关,根除幽门螺杆菌有望降低其发病风险。影响幽门螺杆菌根除的因素包括抗生素耐药性、CYP2C19基因型、药物治疗方案及患者依从性。含克拉霉素的三联治疗方案中增加奥美拉唑和阿莫西林剂量可能克服这些问题,且可能比传统含克拉霉素的三联治疗方案更优。目的:比较改良三联疗法(MTT)和标准三联疗法(STT)作为一线治疗的根除率。材料与方法:本研究为开放标签、多中心、随机对照试验。共有170例经快速尿素酶试验诊断为幽门螺杆菌感染的患者被随机分为两组。第一组接受为期14天的MTT(奥美拉唑20 mg,每日3次;阿莫西林500 mg,每日3次;克拉霉素500 mg,每日2次),第二组接受为期14天的STT(奥美拉唑20 mg,每日2次;阿莫西林1000 mg,每日2次;克拉霉素500 mg,每日2次)。通过¹⁴C-尿素呼气试验评估幽门螺杆菌根除情况。还记录了CYP2C19基因型、克拉霉素耐药性、副作用及患者依从性。结果:每组各有85例患者。意向性分析(ITT)显示MTT组幽门螺杆菌根除率为84.7%,符合方案分析(PP)为91.1%,相比之下,STT组分别为76.5%和87.8%(p = 0.18和0.51)。两组的CYP2C19基因型及患者依从性相似。克拉霉素耐药率为7.0%。副作用均较轻微,两组间无显著差异。结论:MTT并不优于STT。根据本研究,MTT可能不推荐作为泰国幽门螺杆菌感染的一线治疗方法,因为ITT分析显示根除率低于90%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/752a/5494241/35d81607b102/APJCP-18-927-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验